Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 61

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 61
---
 LNPs in mRNA vaccines has expanded interest in their use for other vaccines, gene therapy, and potential treatments for diseases beyond COVID-19. Several outstanding applications of LNP delivery systems by other companies are being developed and successfully implemented across industry.

According to Transparency Market Research published 2023, global liposome drug delivery market was valued at USD 4.8 Bn in 2022.

Nano-Mupirocin: Novel Nanoparticles-based Formulation of a Potent Antibiotic Mupirocin

Mupirocin is an antibiotic with a unique mode of action, not shared by any other therapeutically available antibiotic. However, due to its rapid elimination following injection and high protein binding, current therapeutic use of this well-known agent is limited to topical administration. The novel formulation of Nano-Mupirocin is designed to overcome the challenge of antibiotic resistance, which has emerged as one of the most pressing threats to global health and development.

Antibiotic resistance occurs when bacteria change in a way that makes antibiotics less effective or ineffective against them. This makes infections harder to treat and increases the risk of disease spread, severe illness, disability, and death. Antibiotic resistance is driven by the misuse and overuse of antibiotics in humans, animals, and plants, and is exacerbated by poverty and inequality.

Global Research on Antimicrobial Resistance (GRAM) Project conducted and published by Cambridge University in 2024 demonstrated that globally antibiotic-resistant infections were directly responsible for 1.45 million deaths and contributed to 5.35 million deaths in 2022. In the US alone, antimicrobial resistance was responsible for 47,000 deaths and contributed to 180,000 deaths in 2022. 2These numbers are echoed by the 2022 report published by WHO.

Nano-Mupirocin is a PEGylated nano-liposomal formulation of Mupirocin. Its development originated from a computational study that identified Mupirocin as a suitable candidate for nano-liposomal delivery. The selection for further development was based not only on the chemical structure of Mupirocin, but also on its potential advantages when encapsulated. Mupirocin, an antibiotic with a unique mode of action unlike other commercial antibiotics, is effective against bacteria listed as urgent and serious threats by the Centers for Disease Control and Prevention (“CDC”). Encapsulation in nanoparticles, or liposomes, protects Mupirocin in circulation, enabling its administration through systemic injection.

| 2 | https://www.tropicalmedicine.ox.ac.uk/